Lauren K. McDaniel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lauren K. McDaniel has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Eiko Hayase
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
18 shared publications - Rishika Prasad
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
18 shared publications - Chia-Chi Chang
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
17 shared publications - Christine B. Peterson
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA
17 shared publications - Jeffrey J. Molldrem
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
17 shared publications - Robert R. Jenq
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA
17 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Tsyn-Seq: a T-cell Synapse–Based Antigen Identification Platform
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Tsyn-Seq: a T-cell Synapse–Based Antigen Identification Platform
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Tsyn-Seq: a T-cell Synapse–Based Antigen Identification Platform
Generation of reporter cells overexpressing CaSki cDNA library.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Tsyn-Seq: a T-cell Synapse–Based Antigen Identification Platform
Generation of reporter cells overexpressing CaSki cDNA library.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Tsyn-Seq: a T-cell Synapse–Based Antigen Identification Platform
Activation of Fas-iNFκB reporter in FIR-APCs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Tsyn-Seq: a T-cell Synapse–Based Antigen Identification Platform
Activation of Fas-iNFκB reporter in FIR-APCs.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Tsyn-Seq: a T-cell Synapse–Based Antigen Identification Platform
Tsyn-seq system spike-in assay.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Tsyn-Seq: a T-cell Synapse–Based Antigen Identification Platform
Tsyn-seq system spike-in assay.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Tsyn-Seq: a T-cell Synapse–Based Antigen Identification Platform
Aggregates of interacting target cells and T cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Tsyn-Seq: a T-cell Synapse–Based Antigen Identification Platform
Aggregates of interacting target cells and T cells.
- Open Access
- 13 March 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (6) , 1979-1991
Fecal carbohydrate-degrading bacteria are associated with reduced incidence of lower gastrointestinal GVHD
Lower gastrointestinal graft-versus-host disease (LGI-GVHD) carries morbidity and mortality for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), with critical contributions from the intestinal microbiome. In a retrospective cohort of metagenomic sequencing of stool from patients with allo-HSCT (N = 90), we found that a reduction in specific Parabacteroides and Bacteroides species around the time of engraftment contributes to LGI-GVHD risk. Given the known diverse carbohydrate-degrading functionality of these bacteria, we investigated gene abundances for carbohydrate-active enzymes (CAZymes) and found that Parabacteroides merdae, P distasonis, and Bacteroides ovatus abundances were significantly correlated with CAZymes in patients who did not develop LGI-GVHD compared with those who did. The specific gene abundances of xylosidase, which contribute to the degradation of xylose-containing polysaccharides, were significantly associated with a reduced risk of LGI-GVHD. All these findings show the importance of the carbohydrate-degrading functionality of putative beneficial bacteria in mediating risk of LGI-GVHD.
- 13 March 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (6) , 1979-1991
Open AccessFecal carbohydrate-degrading bacteria are associated with reduced incidence of lower gastrointestinal GVHD
Lower gastrointestinal graft-versus-host disease (LGI-GVHD) carries morbidity and mortality for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), with critical contributions from the intestinal microbiome. In a retrospective cohort of metagenomic sequencing of stool from patients with allo-HSCT (N = 90), we found that a reduction in specific Parabacteroides and Bacteroides species around the time of engraftment contributes to LGI-GVHD risk. Given the known diverse carbohydrate-degrading functionality of these bacteria, we investigated gene abundances for carbohydrate-active enzymes (CAZymes) and found that Parabacteroides merdae, P distasonis, and Bacteroides ovatus abundances were significantly correlated with CAZymes in patients who did not develop LGI-GVHD compared with those who did. The specific gene abundances of xylosidase, which contribute to the degradation of xylose-containing polysaccharides, were significantly associated with a reduced risk of LGI-GVHD. All these findings show the importance of the carbohydrate-degrading functionality of putative beneficial bacteria in mediating risk of LGI-GVHD.
- Top Cited Papers
- 20 February 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (8) , 823-839
Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy
Antibiotic (ABX)–induced microbiome dysbiosis is widespread in oncology, adversely affecting outcomes and side effects of various cancer treatments, including immune checkpoint inhibitors and chimeric antigen receptor T-cell (CAR-T) therapies. In this study, we observed that prior exposure to broad-spectrum ABXs with extended anaerobic coverage such as piperacillin-tazobactam and meropenem was associated with worse anti-CD19 CAR-T therapy survival outcomes in patients with large B-cell lymphoma (N = 422) than other ABX classes. In a discovery subset of these patients (n = 67), we found that the use of these ABXs was in turn associated with substantial dysbiosis of gut microbiome function, resulting in significant alterations of the gut and blood metabolome, including microbial effectors such as short-chain fatty acids (SCFAs) and other anionic metabolites, findings that were largely reproduced in an external validation cohort (n = 58). Broader evaluation of circulating microbial metabolites revealed reductions in indole and cresol derivatives, as well as trimethylamine N-oxide, in patients who received ABX treatment (discovery, n = 40; validation, n = 28). These findings were recapitulated in an immune-competent CAR-T mouse model, in which meropenem-induced dysbiosis led to a systemic dysmetabolome and decreased murine anti-CD19 CAR-T efficacy. Furthermore, we demonstrate that SCFAs can enhance the metabolic fitness of CAR-Ts, leading to improved tumor killing capacity. Together, these results suggest that broad-spectrum ABX deplete metabolically active commensals whose metabolites are essential for enhancing CAR-T efficacy, shedding light on the intricate relationship between ABX exposure, microbiome function and their impact on CAR-T efficacy. This highlights the potential for modulating the microbiome to augment CAR-T immunotherapy. This trial was registered at www.clinicaltrials.gov as #NCT06218602.
- 20 February 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (8) , 823-839
Top Cited PapersAntibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy
Antibiotic (ABX)–induced microbiome dysbiosis is widespread in oncology, adversely affecting outcomes and side effects of various cancer treatments, including immune checkpoint inhibitors and chimeric antigen receptor T-cell (CAR-T) therapies. In this study, we observed that prior exposure to broad-spectrum ABXs with extended anaerobic coverage such as piperacillin-tazobactam and meropenem was associated with worse anti-CD19 CAR-T therapy survival outcomes in patients with large B-cell lymphoma (N = 422) than other ABX classes. In a discovery subset of these patients (n = 67), we found that the use of these ABXs was in turn associated with substantial dysbiosis of gut microbiome function, resulting in significant alterations of the gut and blood metabolome, including microbial effectors such as short-chain fatty acids (SCFAs) and other anionic metabolites, findings that were largely reproduced in an external validation cohort (n = 58). Broader evaluation of circulating microbial metabolites revealed reductions in indole and cresol derivatives, as well as trimethylamine N-oxide, in patients who received ABX treatment (discovery, n = 40; validation, n = 28). These findings were recapitulated in an immune-competent CAR-T mouse model, in which meropenem-induced dysbiosis led to a systemic dysmetabolome and decreased murine anti-CD19 CAR-T efficacy. Furthermore, we demonstrate that SCFAs can enhance the metabolic fitness of CAR-Ts, leading to improved tumor killing capacity. Together, these results suggest that broad-spectrum ABX deplete metabolically active commensals whose metabolites are essential for enhancing CAR-T efficacy, shedding light on the intricate relationship between ABX exposure, microbiome function and their impact on CAR-T efficacy. This highlights the potential for modulating the microbiome to augment CAR-T immunotherapy. This trial was registered at www.clinicaltrials.gov as #NCT06218602.
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from Tsyn-Seq: a T-cell Synapse–Based Antigen Identification Platform
Aggregates of interacting target cells and T cells.
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Tsyn-Seq: a T-cell Synapse–Based Antigen Identification Platform
Aggregates of interacting target cells and T cells.
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from Tsyn-Seq: a T-cell Synapse–Based Antigen Identification Platform
Activation of Fas-iNFκB reporter in FIR-APCs.
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Tsyn-Seq: a T-cell Synapse–Based Antigen Identification Platform
Activation of Fas-iNFκB reporter in FIR-APCs.
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Tsyn-Seq: a T-cell Synapse–Based Antigen Identification Platform
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Tsyn-Seq: a T-cell Synapse–Based Antigen Identification Platform